lactam bridge is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
== Energy release == The Q value is defined as the total energy released in a given nuclear decay. In beta decay, Q is therefore also the sum of the kinetic energies of the emitted beta particle, neutrino, and recoiling nucleus. (Because of the large mass of the nucleus compared to that of the beta particle and neutrino, the kinetic energy of the recoiling nucleus can generally be neglected.) Beta particles can therefore be emitted with any kinetic energy ranging from 0 to Q. A typical Q is around 1 MeV, but can range from a few keV to a few tens of MeV. Since the rest mass of the electron is 511 keV, the most energetic beta particles are ultrarelativistic, with speeds very close to the speed of light. In the case of 187Re, the maximum speed of the beta particle is only 9.8% of the speed of light. The following table gives some examples:
==== Singapore ==== Taco Bell in Singapore existed for a number of years, mostly as combination stores with KFC such as the one that operated at the Funan Digital Life Mall, but in 2008, Taco Bell completely pulled out of Singapore.
== Clinical trials == Sunobinop was generally well tolerated in 3 studies involving 70 healthy subjects at doses that ranged from 0.6 to 30 mg. The most prominent adverse event was dose-dependent sedation/somnolence, which was more common at doses greater than 10 mg. In these studies, most of the absorbed sunobinop was excreted unchanged via rapid renal elimination. The safety and effectiveness of sunobinop has not been evaluated by the FDA. There is no guarantee that sunobinop will successfully complete development or gain FDA approval.
=== Cystine === Cystine is a dimer consisting of two cysteine molecules and the formation of a disulfide bond. This amino acid is a rate limiting substrate used in the SLC7A11 cystine/glutamate transporter and is usually imported into the cell. Cysteine-158 is specifically used in the formation of the disulfide bridge for the protein structure of system Xc-. There are neurotoxins, such as BMAA, that can prevent the intake of cystine, which can lead to decreased extracellular glutamate levels and an increase in oxidative stress.
== Election process == The president is not directly elected by Burmese voters; instead, they are indirectly elected by the Presidential Electoral College (သမ္မတရွေးချယ်တင်မြှောက်ရေးအဖွဲ့), an electoral body made of three separate committees. One committee is composed of MPs who represent the proportions of MPs elected from each Region or State; another is composed of MPs who represent the proportions of MPs elected from each township population; the third is of military-appointed MPs personally nominated by the Defence Services' commander-in-chief. Each of the three committees nominates a presidential candidate. Afterward, all the Pyidaungsu Hluttaw MPs vote for one of three candidates—the candidate with the highest number of votes is elected president, while the other two are elected as vice-presidents. The president serves for a term of 5 years. Should a president resign for any reason or die in office, the Presidential Electoral College will meet and each of the three committees will nominate a candidate to finish out the prior President's term so that the terms of the legislature and presidency are synchronised. The candidate who receives the most votes from the nominees is elected. This process is similar to the one prescribed by the 1947 Constitution, in which MPs from the Parliament's Chamber of Nationalities and Chamber of Deputies elected the president by secret ballot. The President was then responsible for appointing a prime minister (on the advice of the Chamber of Deputies), who was constitutionally recognised as the head of government and led the Cabinet.
Sources: en.wikipedia.org
Glyn Ford and Jonathan Simnett, Silver from the Sea, September/October 1982, Volume 33, Number 5, Saudi Aramco World Archived 2006-11-12 at the Wayback Machine Accessed 17 October 2005 Ballard, Robert D., 2000, The Eternal Darkness, Princeton University Press. Csotonyi, J. T.; Stackebrandt, E.; Yurkov, V. (4 July 2006). "Anaerobic Respiration on Tellurate and Other Metalloids in Bacteria from Hydrothermal Vent Fields in the Eastern Pacific Ocean". Applied and Environmental Microbiology. 72 (7): 4950–4956. Bibcode:2006ApEnM..72.4950C. doi:10.1128/AEM.00223-06. PMC 1489322. PMID 16820492. Koschinsky, Andrea; Garbe-Schönberg, Dieter; Sander, Sylvia; Schmidt, Katja; Gennerich, Hans-Hermann; Strauss, Harald (2008). "Hydrothermal venting at pressure-temperature conditions above the critical point of seawater, 5°S on the Mid-Atlantic Ridge". Geology. 36 (8): 615. Bibcode:2008Geo....36..615K. doi:10.1130/G24726A.1. Catherine Brahic (4 August 2008). "Found: The hottest water on Earth". New Scientist. Retrieved 18 June 2010.
Casa Esperanza Montessori School (K-8) Endeavor Charter School (K-8) Exploris Middle School (1–8) Hope Elementary School (K-5) Longleaf School of the Arts (9–12) Magellan Charter School (3–8) PreEminent Charter School (K-8) Quest Academy (K-8) Raleigh Charter High School (9–12) Torchlight Academy (K-6) Woods Charter School (K-12)
==== MeSH D06.472.317 – gastrointestinal hormones ==== MeSH D06.472.317.152 – cholecystokinin MeSH D06.472.317.152.700 – sincalide MeSH D06.472.317.350 – epidermal growth factor MeSH D06.472.317.400 – gastric inhibitory polypeptide MeSH D06.472.317.410 – gastrin-releasing peptide MeSH D06.472.317.413 – gastrins MeSH D06.472.317.413.593 – pentagastrin MeSH D06.472.317.413.800 – tetragastrin MeSH D06.472.317.469 – glucagon precursors MeSH D06.472.317.469.500 – enteroglucagons MeSH D06.472.317.469.500.500 – glucagon-like peptide 1 MeSH D06.472.317.525 – motilin MeSH D06.472.317.662 – peptide yy MeSH D06.472.317.800 – secretin MeSH D06.472.317.950 – vasoactive intestinal peptide
Nicotine – nicotine has been associated with improved alertness, attention, memory, and motor performance, according to a meta-analysis. However, a 2020 systematic review raised concerns about potential conflicts of interest, noting industry funding in many studies and inconsistent results regarding nicotine's cognitive effects. This review found that over half of the studies published after 2010 had tobacco industry affiliations, often undisclosed.
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.